U.S. flag

An official website of the United States government

NM_006912.6(RIT1):c.268A>G (p.Met90Val) AND RASopathy

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 24, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001192383.2

Allele description [Variation Report for NM_006912.6(RIT1):c.268A>G (p.Met90Val)]

NM_006912.6(RIT1):c.268A>G (p.Met90Val)

Gene:
RIT1:Ras like without CAAX 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1q22
Genomic location:
Preferred name:
NM_006912.6(RIT1):c.268A>G (p.Met90Val)
HGVS:
  • NC_000001.11:g.155904472T>C
  • NG_033885.1:g.11931A>G
  • NM_001256820.2:c.160A>G
  • NM_001256821.2:c.319A>G
  • NM_006912.6:c.268A>GMANE SELECT
  • NP_001243749.1:p.Met54Val
  • NP_001243750.1:p.Met107Val
  • NP_008843.1:p.Met90Val
  • LRG_1372t1:c.268A>G
  • LRG_1372:g.11931A>G
  • LRG_1372p1:p.Met90Val
  • NC_000001.10:g.155874263T>C
  • NM_001256821.1:c.319A>G
  • NM_006912.5:c.268A>G
Protein change:
M107V
Links:
Molecular consequence:
  • NM_001256820.2:c.160A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001256821.2:c.319A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_006912.6:c.268A>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
RASopathy
Synonyms:
rasopathies; Noonan spectrum disorder
Identifiers:
MONDO: MONDO:0021060; MedGen: C5555857

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001360454Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(May 24, 2021)
germlineclinical testing

PubMed (7)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

RIT1 controls actin dynamics via complex formation with RAC1/CDC42 and PAK1.

Meyer Zum Büschenfelde U, Brandenstein LI, von Elsner L, Flato K, Holling T, Zenker M, Rosenberger G, Kutsche K.

PLoS Genet. 2018 May;14(5):e1007370. doi: 10.1371/journal.pgen.1007370.

PubMed [citation]
PMID:
29734338
PMCID:
PMC5937737

Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.

Capelletti M, Dodge ME, Ercan D, Hammerman PS, Park SI, Kim J, Sasaki H, Jablons DM, Lipson D, Young L, Stephens PJ, Miller VA, Lindeman NI, Munir KJ, Richards WG, Jänne PA.

Clin Cancer Res. 2014 Dec 15;20(24):6551-8. doi: 10.1158/1078-0432.CCR-14-1337. Epub 2014 Oct 7.

PubMed [citation]
PMID:
25294908
See all PubMed Citations (7)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001360454.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (7)

Description

Variant summary: RIT1 c.268A>G (p.Met90Val) results in a conservative amino acid change located in the Small GTP-binding protein domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251366 control chromosomes. c.268A>G has been reported in the literature as a de-novo occurrence in multiple fetal cases affected with Noonan Syndrome And Related Conditions (example, Milosavljevic_2016, Quinan-Jones_2019, Becher_2020, Stuurman_2019, Petrovski_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in increased activation of ERK signaling supporting a gain of function outcome (Buschenfelde_2018). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 7, 2024